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Abstract 
Background: Anemone flaccida Fr. Schmidt (Ranunculaceae) (Di Wu in Chinese) is used to treat punch injury and 
rheumatoid arthritis (RA). However, the active compounds and underlying mechanism of action mediating the 
anti‑arthritic effects of A. flaccida remain unclear. This study aims to evaluate the underlying action mechanism of A. 
flaccida crude triterpenoid saponins (AFS) on RA using a type II collagen (CII)‑induced arthritis (CIA) rat model, and 
to assess the anti‑inflammatory effects of the main active compounds of AFS, namely flaccidoside II, anhuienoside 
E, glycoside St‑I4a, hemsgiganoside B, hederasaponin B, and 3‑O‑α‑l‑rhamnopyranosyl (1 → 2)‑β‑d‑glucopyranosyl 
oleanolic acid 28‑O‑β‑d‑glucopyranosyl (1 → 6)‑β‑d‑glucopyranosyl ester.
Methods: Male Wistar rats (n = 50) were randomly separated into five groups (n = 10) and immunized by CII injec‑
tion. AFS (200 or 400 mg/kg) and dexamethasone were orally administered for 30 days after establishing the model. 
The arthritis severity was assessed by paw volume using a plethysmometer. After 30 days of treatment, the right hind 
paws of the rats were obtained. Paw histology was analyzed by hematoxylin and eosin staining, and radiologic imag‑
ing was performed by micro‑computed tomography. MTT assays were used to evaluate the cytotoxicity of AFS and its 
main compounds in RAW264.7 cells. Enzyme‑linked immunosorbent assay kits were used to measure interleukin (IL)‑6 
and tumor necrosis factor (TNF)‑α in serum and supernatants from AFS‑ and main AFS compound‑treated RAW264.7 
cells stimulated by lipopolysaccharide (LPS).
Results: Anemone flaccida crude triterpenoid saponins inhibited redness and swelling of the right hind paw in the 
CIA model. Radiological and histological examinations indicated that inflammatory responses were reduced by AFS 
treatment. Moreover, comparing with untreated rats, serum TNF‑α (P = 0.0035 and P < 0.001) and IL‑6 (P = 0.0058 and 
P = 0.0087) were lower in AFS‑treated CIA rats at the dose of 200 and 400 mg/kg/day. AFS and its main compounds, 
including hederasaponin B, flaccidoside II, and hemsgiganoside B, significantly inhibited TNF‑α (P = 0.0022, P = 0.013, 
P = 0.0015, and P = 0.016) and IL‑6 (P = 0.0175, P < 0.001, P < 0.001, and P < 0.001) production in LPS‑treated 
RAW264.7 cells, respectively.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory 
autoimmune disease characterized by changes in the syn-
ovial tissue. RA is initiated by an infection or tissue injury 
followed by subsequent inflammatory responses, includ-
ing joint pain and swelling, as well as synovial hyper-
plasia, pannus formation, and concomitant destruction 
of cartilage and bone [1]. Although the exact cause and 
pathogenesis of RA remain incompletely understood, 
T-lymphocytes, B-lymphocytes, macrophages, and 
dendritic cells are involved in the inflammation of the 
synovial membrane and cartilage–pannus junction [2]. 
Dysregulated immune cell interactions can induce over-
production of pro-inflammatory cytokines, such as inter-
leukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α, 
resulting in an imbalance between pro-inflammatory and 
anti-inflammatory cytokine activity and joint damage [3].
Despite decades of RA drug development, there remains 
a lack of viable therapeutic approaches for the prevention 
and treatment of RA. Steroidal and nonsteroidal anti-
inflammatory drugs are approved for alleviation of pain 
as well as inflammatory and autoimmune components of 
the disease, without reducing cartilage and bone destruc-
tion of joints. However, long-term administration of these 
drugs can cause severe side effects or toxicity, such as 
cardiovascular risk and gastrointestinal disturbances [4, 
5]. Infliximab has been approved for treatment of RA by 
blocking TNF-α, but its administration must be consid-
ered carefully because of its high cost [6]. Furthermore, 
antibodies can interfere with immune defense. Thus, there 
is an urgent need to develop novel therapeutic agents.
The dry rhizomes of Anemone flaccida Fr. Schmidt 
(Ranunculaceae) (Di Wu in Chinese) are used to heal 
fractures and strengthen bones. Previous phytochemi-
cal studies demonstrated that triterpenoid saponins are 
the main chemical components of this plant, as well as 
the major bioactive constituents [7–9]. Triterpenoid 
saponins from A. flaccida were reported to exhibit anti-
inflammatory [10], anticonvulsant [7], anticancer [7], 
antiviral [11], and immunosuppressive [12] activities. 
However, the roles of A. flaccida triterpenoid saponins 
for the RA inflammatory response remain unclear.
This study aims to evaluate the underlying mecha-
nism of action of A. flaccida crude triterpenoid saponins 
(AFS) on RA using a type II collagen (CII)-induced arthri-
tis (CIA) rat model, and to assess the anti-inflammatory 
effects of the main active compounds of AFS, including 
flaccidoside II, anhuienoside E, glycoside St-I4a, hemsgiga-
noside B, hederasaponin B, and 3-O-α-l-rhamnopyranosyl 
(1  →  2)-β-d-glucopyranosyl oleanolic acid 28-O-β-d-
glucopyranosyl (1  →  6)-β-d-glucopyranosyl ester, by 
detecting TNF-α and IL-6 production in lipopolysaccha-
ride (LPS)-treated RAW264.7 cells.
Methods
Materials
Dexamethasone was purchased from Guangdong Hua-
nan Pharmaceutical Group Co. Ltd. (China). AFS and 
dexamethasone were dissolved in distilled water. Bovine 
CII (2 mg/mL, dissolved in 0.05 M acetic acid), complete 
Freund’s adjuvant (CFA; 4  mg/mL), LPS (Escherichia 
coli 055:B5), and 3-[4,5-dimethylthiazol-2-yl]-2,5-di-
phenyltetrazolium bromide (MTT) were purchased 
from Sigma-Aldrich (USA). TNF-α and IL-6 enzyme-
linked immunosorbent assay (ELISA) kits were obtained 
from eBioscience (USA). Dulbecco’s modified Eagle’s 
medium (DMEM) and all other cell culture products 
were acquired from Life Technologies (USA). The murine 
macrophage cell line RAW264.7 (ATCC No. TIB-71™) 
was purchased from American Type Culture Collection.
Preparation of AFS
Rhizomes of A. flaccida were collected from Changyang 
county, Hubei Province, P.R. China, and authenticated by 
Prof. Guang-Xiong Zhou (Institute of Traditional Chi-
nese Medicine & Natural Products, Jinan University) in 
accordance with previous reports [9, 13, 14]. A voucher 
specimen (No. 130512) was deposited in the Institute 
of Traditional Chinese Medicine and Natural Products, 
Jinan University, Guangzhou, P.R. China.
Powdered air-dried rhizomes of A. flaccida (2.6 kg) were 
extracted with water under reflux three times (first: 20 L, 
3 h; second: 15 L, 1 h; third: 10 L, 1 h). The three extracts 
were combined and concentrated under vacuum to an 
appropriate volume. The concentrated extract was sub-
jected to a D101 macroporous resin column (50 × 200 cm) 
and sequentially eluted with H2O, 10% ethanol, 30% etha-
nol, 70% ethanol, and 95% ethanol (v/v). The 70% ethanol 
solution was collected and concentrated under vacuum to 
obtain the crude AFS fraction (83 g, dry weight).
HPLC analysis of AFS
High performance liquid chromatography (HPLC) analy-
sis was performed using an Agilent 1260 system (Agilent 
Conclusions: Anemone flaccida crude triterpenoid saponins and its main bioactive components, including heder‑
asaponin B, flaccidoside II, and hemsgiganoside B, decreased pro‑inflammatory cytokine levels in a CIA rat model and 
LPS‑induced RAW264.7 cells.
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Corp., USA) equipped with a quaternary pump, an auto 
plate-sampler, a thermostatically controlled column 
apartment, and an evaporative light scattering detector 
(ELSD; Alltech Corp., USA). Chromatographic separa-
tion was carried out on a Cosmosil 5MSII-C18 column 
(250 mm × 4.6 mm, 5 μm) at 30°C with an injection vol-
ume of 10 μL. Gradient elution with solvent A (0.2% formic 
acid in H2O) and solvent B (acetonitrile) was performed at 
a flow rate of 1 mL/min as follows: 20–32% B (10 min); 32% 
B (15 min); 32–100% B (20 min); 100% B (5 min). AFS was 
analyzed for six standard saponins, which were previously 
isolated from the rhizomes of A. flaccida. The structures 
were then identified based on extensive spectroscopic anal-
yses performed in our laboratory. The flaccidoside II con-
tent was obtained directly by an external standard method. 
The contents of the other five saponins (Cx) were calculated 
as ratios between the response of each saponin (Rx) and the 
response of flaccidoside II in a unit concentration (RFII/CFII) 
of the sample solution, using the equation shown below.
Animals
Male Wistar rats (n = 50) [6–8 weeks of age; 120–160 g; 
SPF grade; Certified No. SCXK (Guangdong) 2011-0015] 
were purchased from the Department of Laboratory Ani-
mal Science at Sun Yat San University (China). All rats 
were maintained under specific pathogen-free conditions 
with a standard diet, and provided with water ad libitum. 
The animals were housed under standard laboratory con-
ditions for 1 week prior to experiments. All experimental 
procedures complied with the Care and Use of Labora-
tory Animals, and were approved by the local Animal 
Ethics Committee of Jinan University.
Induction of arthritis and drug administration
Experimental arthritis in Wistar rats was induced as 
described previously [15, 16]. Briefly, 50 animals were 
arbitrarily divided into five groups (n  =  10): normal 
control; CIA; CIA + AFS (200 mg/kg/day); CIA + AFS 
(400 mg/kg/day); and CIA + dexamethasone (0.272 mg/
kg/day). Bovine CII was dissolved in 0.05  M acetic acid 
(2.0  mg/mL) and completely emulsified with CFA at 
a ratio of 1:1. The rats were immunized by intradermal 
injection of 100 μg CII in CFA into the base of the tail. 
The rats in the normal control group did not receive an 
injection. The day of the immunization was defined as 
day 1. After the immunization with CII, the rats in the 
AFS treatment groups received an intragastric dose of 
AFS (200 or 400 mg/kg/day) for 30 days, while the posi-
tive control group received dexamethasone (0.272  mg/
kg/day). The CIA and normal control groups were 






Following the immunization, the arthritic condition 
of each paw, including the severity of joint redness and 
swelling, was observed and evaluated on alternate days as 
previously described [15]. Paws were marked with a red 
line 0.5  cm above the ankle joint, and paw volume was 
measured three times below the red line using a paw 
volume plethysmometer. The average of three measure-
ments was considered to be the measured volume. Paw 
swelling (∆mL) was calculated by subtracting the paw 
volume on day 1 from the measured volume.
Histological analysis of paws
The rats were euthanized on day 30 after the CII injec-
tion, and the right hind paws of the rats were obtained, 
stored in 10% neutral formalin, decalcified with 20% eth-
ylenediaminetetraacetic acid for 6  weeks, dehydrated, 
and embedded in paraffin. Sections were cut along the 
longitudinal axis, mounted, and stained with hematoxy-
lin and eosin (H&E) [17].
Radiography
Radiography was performed on the hind paw ankle. The 
destruction of bone and cartilage was classified and radi-
ologic changes were observed using micro-computed 
tomography (micro-CT) (ZKKS-MCT-Sharp; Zhongke 
Kaisheng Medical Technology Co. Ltd., China). The 3D 
bone architecture was revealed in exquisite detail at 
20-μm spatial resolution.
Determination of serum TNF‑α and IL‑6
Rats were anesthetized on day 30, and blood was col-
lected from the abdominal aorta and stored at 4°C over-
night. The supernatant was collected after centrifugation 
at 3,000×g (Eppendorf 5417R; Eppendorf, Germany) for 
10 min. The serum TNF-α and IL-6 levels were measured 
using specific ELISA kits according to the manufacturer’s 
recommendations. A standard curve was performed for 
each plate and used to calculate the absolute concentra-
tions of the indicated cytokines.
Anti‑inflammatory activity of AFS and its main compounds 
in vitro
Cell culture
RAW264.7 murine macrophages were cultured in 
DMEM supplemented with 10% (v/v) heat-inactivated 
fetal bovine serum (FBS), 2 mM glutamine, 1 mM sodium 
pyruvate, 4.5 g/L glucose, 100 μg/mL streptomycin, and 
100 U/mL penicillin at 37°C in a humidified atmosphere 
containing 5% CO2.
MTT assay
RAW264.7 murine macrophages (5  ×  103  cells/well) 
were cultured in a 96-well plate containing DMEM 
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supplemented with 10% FBS for 24  h until they were 
nearly confluent. The cells were then treated with AFS 
(0.055 mg/mL) or AFS-derived compounds (30 μM) for 
24 h. The cells were washed twice with phosphate-buff-
ered saline and incubated with 30 μL of MTT (5 mg/mL) 
for 4 h at 37°C. The medium was discarded, and 100 μL 
of dimethyl sulfoxide (DMSO) was added. After 15 min 
of incubation, the absorbances were measured at 570 nm 
using a microplate reader (Synergy HT; Bio Tek, USA).
TNF‑α and IL‑6 production
To evaluate the anti-inflammatory potential of AFS and 
its main components, RAW264.7 murine macrophages 
(5  ×  105  cells/well) were cultured in 6-well microplate 
for 24 h. AFS and its main compounds were initially dis-
solved in DMSO as stock solutions of 0.22  g/mL and 
100  mM, respectively, and then diluted to final concen-
trations of 0.055  mg/mL and 30  μM in DMEM. Cells 
were pretreated with AFS and its main compounds for 
1  h before stimulation with 100  ng/mL LPS. The acti-
vated cells were further incubated for 6  h to measure 
TNF-α production or 24 h to measure IL-6 production. 
Supernatants were collected and the concentrations of 
TNF-α and IL-6 were determined using specific ELISA 
kits. Control cells were grown under identical conditions, 
but without the test compounds and LPS. In addition, all 
compounds were incubated with RAW264.7 cells under 
identical conditions in the absence of LPS.
Statistical analysis
Data were presented as mean ± SD from three or more 
experiments using the Origin 9 statistical package 
(OriginLab, USA). Student’s t-test and one-way analysis 
of variance (ANOVA) for parametric analysis was used to 
compare groups and perform multigroup comparisons. 
The Mann–Whitney U test was used to analyze non-
parametric data. A P value less than 0.05 was considered 
to be statistically significant, and a P value less than 0.01 
was considered very statistically significant. Exact P val-
ues were shown unless P < 0.001. Dose-dependency was 
determined visually by observing the trends of the data.
Results
HPLC analysis of AFS
There were significant differences in the quantities of the 
six main saponins in AFS (Fig. 1). The flaccidoside II con-
tent was the highest (28.1%), followed by anhuienoside E 
(9.5%), glycoside St-I4a (8.9%), hemsgiganoside B (6.2%), 
hederasaponin B (5.6%), and 3-O-α-l-rhamnopyranosyl 
(1  →  2)-β-d-glucopyranosyl oleanolic acid 28-O-β-d-
glucopyranosyl (1 → 6)-β-d-glucopyranosyl ester (3.9%). 
The total amount of the six main saponins in AFS was 
63.2%.
Effects of AFS on RA symptoms in CIA rats
Systemic arthritis was induced by injecting CII and 
CFA on day 1. Onset of arthritis generally occurred 
at 10  days after the immunization. Clinical manifesta-
tions, such as functional impairment and swollen red 
paws, were observed (Fig. 2A), and the maximal clinical 
symptoms were achieved at 19 days after the immuniza-
tion. There was a significant increase in paw volume in 
the CIA model rats compared with the normal control 
rats (Fig.  2B; P  <  0.001). Both doses of AFS (200 and 
400 mg/kg) significantly and dose-dependently decreased 
the paw edema volume and redness compared with the 
CIA group (P < 0.001 and P < 0.001, respectively). Dex-
amethasone (0.272  mg/kg) strongly inhibited arthritis 
(P = 0.0013).
AFS treatment decreased immune‑mediated inflammation 
and joint damage in CIA rats
Notable synovial proliferation, granulocyte and mono-
nuclear cell infiltration of the synovial cavity, and par-
tial cartilage and bone destruction were observed in the 
right hind ankle joints of the CIA rats using H&E stain-
ing (Fig.  3a, b). Treatment with 200 or 400  mg/kg AFS 
remarkably reduced the synovial hyperplasia and inflam-
matory cell infiltration compared with the CIA rats 
(Fig.  3c, d). Furthermore, oral administration of dexa-
methasone significantly reduced the immune cell infil-
tration, tissue hyperplasia, cartilage damage, and bone 
erosion compared with the CIA rats (Fig. 3e).
Radiography was performed on the hind paws after 
euthanasia. Radiological changes, such as soft tissue 
swelling and bone erosion, were observed in the CIA rats 
(Fig. 4a, b). In contrast, the rats treated with AFS showed 
a significant reduction in soft tissue swelling and carti-
lage and bone destruction. Joint space enlargement and 
thickening of the periosteum were ameliorated after AFS 
treatment (Fig. 4c, d).
AFS decreased TNF‑α and IL‑6 levels in serum
Low levels of TNF-α and IL-6 were observed in the 
serum of the normal control rats (Fig. 5). However, these 
cytokines were significantly increased in the serum of the 
CIA rats (P = 0.0042 and P < 0.001, respectively). Treat-
ment with AFS at 200 mg/kg (P = 0.0035 and P = 0.0058) 
and 400  mg/kg (P  <  0.001 and P  =  0.0087) markedly 
inhibited the production of TNF-α and IL-6, respectively, 
in the serum of the CIA rats.
AFS and its main components suppressed TNF‑α and IL‑6 
production in LPS‑treated murine macrophages
RAW264.7 cells were pretreated with AFS and the indi-
vidual compounds such as hederasaponin B, flaccido-
side II, hemsgiganoside B, 3-O-α-l-rhamnopyranosyl 
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(1  →  2)-β-d-glucopyranosyl oleanolic acid 28-O-β-
d-glucopyranosyl (1  →  6)-β-d-glucopyranosyl ester, 
anhuienoside E, and glycoside St-I4a at concentrations 
of 0.055 mg/mL and 30 μM, respectively, which did not 
induce cytotoxicity (P  =  0.178, P  =  0.263, P  =  0.117, 
P = 0.488, P = 0.157, P = 0.345, and P = 0.407), followed 
by stimulation with 100  ng/mL LPS to investigate the 
effects of AFS and its main components on LPS-induced 
TNF-α and IL-6 production (Fig. 6a). Pretreatment with 
3-O-α-l-rhamnopyranosyl (1  →  2)-β-d-glucopyranosyl 
oleanolic acid 28-O-β-d-glucopyranosyl (1  →  6)-β-d-
glucopyranosyl ester, anhuienoside E, and glycoside St-
I4a significantly inhibited IL-6 production in LPS-treated 
macrophages (Fig. 6c; P < 0.001, P < 0.001, and P < 0.001, 
respectively). Furthermore, AFS, hederasaponin B, flac-
cidoside II, and hemsgiganoside B, significantly inhibited 
both TNF-α (Fig. 6b; P = 0.0022, P = 0.013, P = 0.0015, 
and P = 0.016, respectively) and IL-6 (Fig. 6c; P = 0.0175, 
P < 0.001, P < 0.001, and P < 0.001, respectively) produc-
tion in LPS-treated macrophages.
Discussion
In the present study, oral administration of AFS from 
A. flaccida significantly inhibited joint swelling, syno-
vial hyperplasia, and inflammatory cell infiltration, 
thereby alleviating joint damage in CIA rats. Further-
more, AFS remarkably reduced the TNF-α and IL-6 
levels in the serum of these rats. Triterpenoid saponins 
were the major active components of AFS, and most 
of these components as well as AFS inhibited TNF-α 
and IL-6 production in LPS-stimulated RAW264.7 
macrophages.
Fig. 1 HPLC‑ELSD chromatograms of standard saponins (A) and AFS (B). (a) Anhuienoside E. (b) Glycoside St‑I4a. (c) 3‑O‑α‑l‑Rhamnopyranosyl 
(1 → 2)‑β‑d‑glucopyranosyl oleanolic acid 28‑O‑β‑d‑glucopyranosyl (1 → 6)‑β‑d‑glucopyranosyl ester. (d) Hemsgiganoside B. (e) Flaccidoside II. (f) 
Hederasaponin B.
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The phytochemical and pharmacological properties of 
A. flaccida have been studied extensively. Triterpenoid 
saponins may contribute to the anti-inflammatory and 
immunosuppressive activities of A. flaccida both in vivo 
and in vitro [12]. Our chemical analysis revealed that AFS 
contained six major triterpenoid saponins, namely flacci-
doside II, anhuienoside E, glycoside St-I4a, hemsgigano-
side B, hederasaponin B, and 3-O-α-l-rhamnopyranosyl 
(1  →  2)-β-d-glucopyranosyl oleanolic acid 28-O-β-
d-glucopyranosyl (1  →  6)-β-d-glucopyranosyl ester. 
Of these, flaccidoside II and glycoside St-I4a inhibited 
LPS-stimulated overexpression of cyclooxygenase-2 and 
prostaglandin E2, which are involved in inflammatory 
diseases [7]. Hederasaponin B suppressed N-formyl-
methionyl-leucyl-phenylalanine-induced superoxide gen-
eration in human neutrophils [18]. In the present study, 
the six main saponins in AFS possessed anti-inflamma-
tory activity, through the suppression of TNF-α and IL-6 
production in LPS-stimulated RAW264.7 macrophages. 
Moreover, the AFS used in the present study contained 
63.2% triterpenoid saponins, including flaccidoside II 
(28.1%), glycoside St-I4a (8.9%), and hederasaponin B 
(5.6%).
The AFS-administered rats showed marked reductions 
in paw volume compared with the CIA model rats. Both 
synovial tissue damage and bone destruction in the joint 
are hallmarks of RA caused by thickening of the synovial 
lining and the formation of invasive pannus tissue [3, 19]. 
Synovial hyperplasia and inflammatory cell infiltration in 
the joint were significantly decreased in the AFS-treated 
rats compared with the CIA rats, and these effects were 
confirmed by the results of micro-CT examination.
Although published data regarding the mechanism by 
which A. flaccida prevents RA are limited, pro-inflam-
matory cytokines and mediators are involved in the 
pathogenesis of arthritis [3, 20]. Among these, TNF-α 
is one of the most important cytokines involved in RA, 
causing synovial inflammation and hyperplasia, and 
thereby facilitating the degradation of articular cartilage 
and bone [21, 22]. A TNF-α-specific antibody attenuated 
the symptoms of spontaneously developed arthritis in 
human TNF-α transgenic mice [5]. Prophylactic admin-
istration of soluble chimeric TNF-α receptors reduced 
the incidence and severity of RA in a mouse model [23]. 
These findings might be related to the ability of TNF-α 
inhibitors to induce inflammatory cell apoptosis, exert 
direct cytotoxicity, and alter the influx and efflux of 
inflammatory cells in joints [24]. Moreover, Romano 
et al. [25] revealed that TNF-α inhibitors induced synovi-
ocyte apoptosis by modulating the Fas/FasL death recep-
tor pathway. IL-6 is a soluble cytokine that regulates local 
inflammation and immune responses [26]. In RA, IL-6 is 
abundantly expressed in the synovial tissue, and causes 
bone destruction and the development of osteoporosis by 
promoting synoviocyte proliferation and osteoclast dif-
ferentiation [27, 28]. IL-6 also enhances angiogenesis and 
Fig. 2 Effects of AFS on paw swelling. A Photographs of the hind paws at 30 days after the CII immunization. B The severity of arthritis during the 
course of CIA was determined by measuring the volume of the hind paw using a paw volume plethysmometer. Data were expressed as mean ± SD 
(n = 10) (##P < 0.01 CIA group vs. normal control group, *P < 0.05, **P < 0.01 treatment groups vs. CIA group).
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increases vascular permeability of synovial tissue by stim-
ulating excess production of vascular endothelial growth 
factor. In addition, IL-6 promoted Th17 differentiation 
and inhibited transforming growth factor-β-induced reg-
ulatory T cell differentiation, thereby disrupting immu-
nological tolerance [29, 30]. The serum TNF-α and IL-6 
levels were markedly decreased in the AFS-treated rats, 
and the main components of AFS significantly inhibited 
LPS-induced TNF-α and IL-6 production in vitro. These 
results suggest that AFS improved the symptoms and 
signs of RA, probably through inhibition of TNF-α and 
IL-6 production.
Conclusions
Anemone flaccida crude triterpenoid saponins and its 
main bioactive components such as hederasaponin B, 
flaccidoside II, and hemsgiganoside B decreased pro-
inflammatory cytokine levels in a CIA rat model and 
LPS-induced RAW264.7 cells.
Fig. 3 Effects of AFS on histopathological changes. Histological analysis of paws was performed after 30 days of AFS treatment. The upper left 
images showed histologic staining of ankle joints and the right bottom showed enlarged   images of partial area of the upper left images.(f) site of 
bone erosion; (g) site of cartilage damage; (h) site of synovial inflammation. Original magnification, ×100.
Fig. 4 Effects of AFS on joint damage and bone structure in CIA. 
Representative radiographs obtained after 30 days of AFS treatment 
demonstrating remarkable amelioration of the articular destruction. 
Arrows indicated remarkable soft tissue swelling and large bone 
erosion.
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AFS: Anemone flaccida crude triterpenoid saponins; ATCC: American Type Cul‑
ture Collection; CII: type II collagen; CIA: type II collagen induced‑arthritis; CFA: 
complete Freund’s adjuvant; DMEM: Dulbecco’s modified Eagle’s medium; 
DMSO: dimethyl sulfoxide; ELISA: enzyme‑linked immunosorbent assay; ELSD: 
evaporative light scattering detector; FBS: fetal bovine serum; HPLC: high 
performance liquid chromatography; IL‑6: interleukin‑6; IL‑1: interleukin‑1; LPS: 
lipopolysaccharide; MTT: 3‑[4,5‑dimethylthiazol‑2‑yl]‑2,5‑diphenyltetrazolium 
bromide; micro‑CT: micro‑computed tomography; RA: rheumatoid arthritis; 
SD: standard deviation; TNF‑α: tumor necrosis factor‑alpha.
Fig. 5 Effects of AFS on cytokine production in rat serum. a The concentrations of TNF‑α and b IL‑6 in serum collected from CIA rats treated with 
AFS. Data were expressed as means ± SD (n = 10).
Fig. 6 Effects of AFS and its components on LPS‑induced TNF‑α and IL‑6 production in macrophages. a Cytotoxicity in RAW264.7 cells treated with 
AFS and its main components. RAW264.7 murine macrophages were cultured in a 96‑well plate for 24 h, and then incubated with or without AFS 
(0.055 mg/mL) or its main components (30 μM) for 24 h. Cell proliferation was determined by the MTT assay. b–c Inhibitory effects of AFS compo‑
nents on LPS‑induced TNF‑α and IL‑6 release in macrophages. Cells were incubated with AFS (0.055 mg/mL) or its main components (30 μM) for 
1 h, followed by stimulation with or without LPS (100 ng/mL). The production of TNF‑α and IL‑6 in culture supernatants was measured by ELISA. 
Data were presented as mean ± SD of three independent experiments.
Page 9 of 9Liu et al. Chin Med  (2015) 10:20 
Authors’ contributions
WCY, MML and YW conceived and designed the study. QL, XZZ, RBF, ZL, GMO, 
GYW and XFG performed the experiments and collected the data. QL, XZZ 
and MML wrote the manuscript. YLL, WCY and MML revised the work. All 
authors read and approved the final manuscript.
Author details
1 College of Pharmacy, Jinan University, Guangzhou 510632, People’s Republic 
of China. 2 Guangdong Province Key Laboratory of Pharmacodynamic Constit‑
uents of TCM and New Drugs Research, Jinan University, Guangzhou 510632, 
People’s Republic of China. 3 Guangzhou Jinan Biomedicine Research 
and Development Center, National Engineering Research Center of Genetic 
Medicine, Jinan University, Guangzhou 510632, People’s Republic of China. 
Acknowledgements
This work was supported financially by the Natural Science Foundations of 
China (81202427, 81302654), Key Laboratory for the Chemistry and Molecular 
Engineering of Medicinal Resources (Guangxi Normal University), and Ministry 
of Education of China (No. CMEMR2013‑B04), Foundation for Distinguished 
Young Talents in Higher Education of Guangdong, China (LYM11024), the 
Science and Technology Planning Project of Guangdong Province (No. 
2012A080204005) and the Project of Guangdong Provincial Administration of 
traditional Chinese medicine (No. 20121161).
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 17 October 2014   Accepted: 28 June 2015
References
 1. Parolini O, Souza‑Moreira L, O’Valle F, Magatti M, Hernandez‑Cortes 
P, Gonzalez‑Rey E et al (2014) Therapeutic effect of human amniotic 
membrane‑derived cells on experimental arthritis and other inflamma‑
tory disorders. Arthritis Rheumatol 66:327–339
 2. Bresnihan B (1999) Pathogenesis of joint damage in rheumatoid arthritis. 
J Rheumatol 26:717–719
 3. Burmester GR, Feist E, Dörner T (2013) Emerging cell and cytokine targets 
in rheumatoid arthritis. Nat Rev Rheumatol 10:77–88
 4. Cessak G, Kuzawinska O, Burda A, Lis K, Wojnar M, Mirowska‑Guzel D et al 
(2014) TNF inhibitors––mechanisms of action, approved and off‑label 
indications. Pharmacol Rep 66:836–844
 5. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D et al 
(1991) Transgenic mice expressing human tumour necrosis factor: a 
predictive genetic model of arthritis. EMBO J 10:4025–4031
 6. Bevaart L, Vervoordeldonk MJ, Tak PP (2010) Evaluation of therapeutic 
targets in animal models of arthritis: how does it relate to rheumatoid 
arthritis? Arthritis Rheum 62:2192–2205
 7. Han L‑T, Fang Y, Li M‑M, Yang H‑B, Huang F (2013) The antitumor effects 
of triterpenoid saponins from the Anemone flaccida and the underlying 
mechanism. Evid Based Complement Altern Med 2013:1–8
 8. Han L, Huang F (2009) Studies on triterpenoid saponins in the rhizome of 
Anemone flaccida. Zhong yao cai 32:1059–1062
 9. Huang X‑J, Tang J‑Q, Li M‑M, Liu Q, Li Y‑L, Fan C‑L et al (2014) Triterpenoid 
saponins from the rhizomes of Anemone flaccida and their inhibitory 
activities on LPS‑induced NO production in macrophage RAW264. 7 cells. 
J Asian Nat Prod Res 16:910–921
 10. Liu Q, Zhang L, Li X, Guo T, Wang P, Li Y (2009) Efficient synthesis of 
flaccidoside II, a bioactive component of Chinese folk medicine Di Wu. J 
Carbohyd Chem 28:506–519
 11. Song J, Yeo S‑G, Hong E‑H, Lee B‑R, Kim J‑W, Kim J et al (2014) Antiviral 
activity of hederasaponin B from Hedera helix against Enterovirus 71 
subgenotypes C3 and C4a. Biomol Ther 22:41–46
 12. Bing F‑H, Han L‑T, Zhang G‑B, Yi Y‑D (2008) Chemical constituents of 
Rhizome of Anemone flaccida and their immuno‑suppressive activities 
in vitro. J China Pharm Univ 6:496–499
 13. Joshi VC, Avula B, Khan IA (2008) Authentication of Stephania tetrandra 
S. Moore (Fang Ji) and differentiation of its common adulterants using 
microscopy and HPLC analysis. J Nat Med 62:117–121
 14. Tam C‑F, Peng Y, Liang Z‑T, He Z‑D, Zhao Z‑Z (2006) Application of micro‑
scopic techniques in authentication of herbal tea—Ku‑Ding‑Cha. Microsc 
Res Tech 69:927–932
 15. Matsumoto I, Inoue A, Takai C, Umeda N, Tanaka Y, Kurashima Y et al 
(2014) Regulatory roles of tumor necrosis factor alpha‑induced proteins 
(TNFAIPs) 3 and 9 in arthritis. Clin Immunol 153:73–78
 16. Huang G‑J, Huang Q‑M (2008) Animal Model in Medical Experiment: 
development and application, vol 10. Chemical Industry Press, Beijing, pp 
479‑480
 17. Lu Y, Xiao J, Wu Z‑W, Wang Z‑M, Hu J, Fu H‑Z et al (2012) Kirenol exerts a 
potent anti‑arthritic effect in collagen‑induced arthritis by modifying the 
T cells balance. Phytomedicine 19:882–889
 18. Chen X, Lu J, He W, Chi H, Yamashita K, Manabe M et al (2009) Antiper‑
oxidation activity of triterpenoids from rhizome of Anemone raddeana. 
Fitoterapia 80:105–111
 19. Koch B, Locher P, Burmester GR, Mohr W, Kalden JR (1984) The tissue 
architecture of synovial membranes in inflammatory and non‑inflamma‑
tory joint diseases. II. The localization of mononuclear cells as detected 
by monoclonal antibodies directed against T‑lymphocyte subsets and 
natural killer cells. Rheumatol Int 4:79–85
 20. Wright HL, Moots RJ, Edwards SW (2014) The multifactorial role of neutro‑
phils in rheumatoid arthritis. Nat Rev Rheumatol 10:593–601
 21. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N 
Engl J Med 365:2205–2219
 22. Makrygiannakis D, Catrina AI (2012) Apoptosis as a mechanism of action 
of tumor necrosis factor antagonists in rheumatoid arthritis. J Rheumatol 
39:679–685
 23. Yamaguchi N, Ohshima S, Umeshita‑Sasai M, Nishioka K, Kobayashi H, 
Mima T et al (2003) Synergistic effect on the attenuation of collagen 
induced arthritis in tumor necrosis factor receptor I (TNFRI) and interleu‑
kin 6 double knockout mice. J Rheumatol 30:22–27
 24. Christodoulou C, Choy EH (2006) Joint inflammation and cytokine inhibi‑
tion in rheumatoid arthritis. Clin Exp Med 6:13–19
 25. Romano E, Terenzi R, Manetti M, Peruzzi F, Fiori G, Nacci F et al (2014) 
Disease activity improvement in rheumatoid arthritis treated with tumor 
necrosis factor‑alpha inhibitors correlates with increased soluble Fas 
levels. J Rheumatol 41:1961–1965
 26. Yoshida Y, Tanaka T (2014) Interleukin 6 and rheumatoid arthritis. BioMed 
Res Int 2014:1–12
 27. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I et al (1996) 
Interleukin‑6 and soluble interleukin‑6 receptors in the synovial fluids 
from rheumatoid arthritis patients are responsible for osteoclast‑like cell 
formation. J Bone Miner Res 11:88–95
 28. Palmqvist P, Persson E, Conaway HH, Lerner UH (2002) IL‑6, leukemia 
inhibitory factor, and oncostatin M stimulate bone resorption and 
regulate the expression of receptor activator of NF‑kappa B ligand, osteo‑
protegerin, and receptor activator of NF‑kappa B in mouse calvariae. J 
Immunol 169:3353–3362
 29. Zambrano‑Zaragoza JF, Romo‑Martinez EJ, Duran‑Avelar Mde J, Garcia‑
Magallanes N, Vibanco‑Perez N (2014) Th17 cells in autoimmune and 
infectious diseases. Int J Inflam 2014:651503
 30. Kimura A, Kishimoto T (2010) IL‑6: regulator of Treg/Th17 balance. Eur J 
Immunol 40:1830–1835
